文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

作者信息

Mach François, Baigent Colin, Catapano Alberico L, Koskinas Konstantinos C, Casula Manuela, Badimon Lina, Chapman M John, De Backer Guy G, Delgado Victoria, Ference Brian A, Graham Ian M, Halliday Alison, Landmesser Ulf, Mihaylova Borislava, Pedersen Terje R, Riccardi Gabriele, Richter Dimitrios J, Sabatine Marc S, Taskinen Marja-Riitta, Tokgozoglu Lale, Wiklund Olov

出版信息

Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455.

DOI:10.1093/eurheartj/ehz455
PMID:31504418
Abstract
摘要

相似文献

[1]
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

Eur Heart J. 2020-1-1

[2]
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.

Atherosclerosis. 2019-11

[3]
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.

Eur Heart J. 2016-10-14

[4]
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).

Atherosclerosis. 2016-10

[5]
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Atherosclerosis. 2011-7

[6]
Do we need a redefinition of the cardiovascular risk categories used in the 2019 ESC/EAS guidelines on dyslipidaemias?

Eur Heart J. 2020-6-21

[7]
The changing landscape of lipid-lowering therapy after the new ESC/EAS guidelines for the management of dyslipidaemias: Launching the era of triple hypolipidaemic therapy in very high risk patients.

Atherosclerosis. 2020-1

[8]
A clinical perspective on the 2019 ESC/EAS guidelines for the management of dyslipidaemias: PCSK-9 inhibitors for all?

Eur Heart J. 2020-6-21

[9]
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Atherosclerosis. 2011-7

[10]
New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus?

Eur J Cardiovasc Prev Rehabil. 2011-10

引用本文的文献

[1]
Prescription of lipid-lowering drugs and their association with hospitalization for ST-elevation myocardial infarction (STEMI) in Germany in 2010-2022.

Clin Res Cardiol. 2025-9-8

[2]
European survey on metabolic and cardiovascular risk in Cushing syndrome.

J Endocrinol Invest. 2025-9-6

[3]
Divergence in Estimated Risks and Actual Rates of Atherosclerotic Cardiovascular Events and their Management in a Longitudinal Cohort of Patients with Dermatomyositis with Skin Involvement.

JID Innov. 2025-7-7

[4]
The challenge of secondary cardiovascular prevention in very high Lipoprotein (a) level: a case report.

Eur Heart J Case Rep. 2025-8-9

[5]
Comparison of Artificial Intelligence Models and Human Experts in Managing Dyslipidemia: Assessment of Adherence to Clinical Guidelines.

Cureus. 2025-8-31

[6]
The Gulliver syndrome: a conceptual framework to address therapeutic inertia in patients with borderline cardiovascular risk profiles.

Front Cardiovasc Med. 2025-8-14

[7]
Impact of severe dyslipidemia on renal function: A cross-sectional study.

Medicine (Baltimore). 2025-8-29

[8]
From guidelines to practice: LDL-C achievement in very high cardiovascular risk patients - analysis of the EDHIPO MARCA registry.

Lipids Health Dis. 2025-9-2

[9]
Efficacy, safety and cost-effectiveness of 40 mg versus 80 mg atorvastatin in a Sri Lankan cohort with acute coronary syndrome: a protocol for a single-centre randomised controlled clinical trial.

Trials. 2025-9-1

[10]
Association between dynamic changes in the triglyceride-glucose index and prognosis in patients with acute ST-segment elevation myocardial infarction.

Cardiovasc Diabetol. 2025-9-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索